CEL-SCI raises $10M in common stock offering
CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC for a registered direct offering of 1,111,200 shares of common stock at $9.00 per share.
Rhea-AI Filing Summary
CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC for a registered direct offering of 1,111,200 shares of common stock at $9.00 per share. The offering closed on August 29, 2025, generating gross proceeds of approximately $10,000,800 before fees and expenses. CEL-SCI plans to use the net proceeds to continue developing its Multikine program, as well as for general corporate purposes and working capital.
The company will pay the placement agent a 7.0% cash fee on gross proceeds and reimburse certain expenses up to $185,000. For 30 days after closing, CEL-SCI agreed not to issue or register additional equity securities, subject to exceptions, and its directors and officers agreed to 45-day lock-ups on sales or transfers of company securities. The shares were sold under an effective Form S-3 shelf registration and related prospectus supplement.
Positive
- None.
Negative
- None.
Insights
CEL-SCI raises about $10M in new equity, adding near-term dilution but strengthening cash resources.
CEL-SCI completed a registered direct equity offering of 1,111,200 common shares at $9.00 per share, for $10,000,800 in gross proceeds. This type of transaction increases the share count but provides immediate cash without adding debt. The shares were issued under an effective Form S-3 shelf registration with a prospectus supplement dated August 27, 2025.
Net proceeds, after a 7.0% placement fee and up to $185,000 of reimbursed expenses, are earmarked to fund continued development of Multikine, plus general corporate purposes and working capital. Short lock-up periods apply: 30 days restricting new company issuances or registrations (with exceptions) and 45 days restricting director and officer sales. The overall impact depends on how effectively CEL-SCI deploys this capital into its development pipeline.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity offering did CEL-SCI (CVM) complete in August 2025?
CEL-SCI completed a registered direct offering of 1,111,200 shares of its common stock at an offering price of $9.00 per share, under an effective Form S-3 shelf registration and an August 27, 2025 prospectus supplement.
How much cash did CEL-SCI raise in this stock offering?
The transaction generated gross proceeds of approximately $10,000,800 before deducting placement agent fees and other offering expenses payable by CEL-SCI.
How will CEL-SCI use the proceeds from the August 2025 offering?
CEL-SCI intends to use the net proceeds from the offering to fund the continued development of Multikine, and for general corporate purposes and working capital.
What fees will CEL-SCI pay to the placement agent ThinkEquity?
Under the Placement Agency Agreement, CEL-SCI agreed to pay ThinkEquity a cash fee equal to 7.0% of the gross proceeds of the offering and to reimburse certain expenses, including legal fees, in an aggregate amount up to $185,000.
Are there any lock-up or issuance restrictions following CEL-SCI’s offering?
For 30 days from the closing of the offering, CEL-SCI agreed not to issue or agree to issue most additional equity or file registration statements, subject to exceptions. In addition, each director and officer agreed, via lock-up agreements, not to sell or transfer company securities they hold for 45 days from the closing, subject to certain exceptions.
AI-generated analysis. How Rhea-AI works. Not financial advice.